1
BIO 2070 MICRO WEEK 5 MIDTERM STUDY GUIDE
Brief description of HIV/AIDS
Living in the state that has one of the highest rate for individuals with AIDS
or HIV makes this disease a relevant topic that is near to me. I am so concerned
about our society especially the younger generations when it comes to the wide
rapid spread of AIDS throughout Georgia. According to the Center for Disease
Control CDC, every 1 in 51 persons in Georgia would be diagnosed with HIV
(CDC, 2016). HIV stands for human immunodeficiency virus. When left untreated,
HIV can lead to an acquired immunodeficiency syndrome (AIDS).
Work conducted by government departments to mitigate the impact of
HIV/AIDS.
The United States is working diligently with the Obama’s administration to
fight, cure, and prevent HIV. For the upcoming fiscal year President Obama has set
aside $788 million dollars for domestic HIV/AIDS prevention and research at the
CDC (CDC, 2016). There are many different studies being conducted to mitigate
, 2
the impact that HIV has on the US. I am going to choose one to discuss which is
PrEP. PrEP (pre-exposure prophylaxis) is used as an anti-HIV drug for individuals
who are not diagnosed with HIV. PrEP was released in 2014. When PrEP is taking
daily along with Truvada it reduces a person from being infected by 92 percent
(CDC, 2014).
Investigations, research studies, and other surveillance data analyses regarding
HIV/AIDS.
There is not a cure for HIV as of yet so, there are still 2.7 million people
infected with HIV in the world. Since, researchers cannot cure the infected patients
they decided to come up with a solution to curb the rapid spread of HIV. The first
phases of the PrEP study were administrated as a topical cream that was inserted
vaginally or rectally before and after sex but, not to be used no more than twice a
day. This study revealed promising results and allow researchers to experiment
more with PrEP. In 2007 phase two and three of this study was administered orally
to the participants and it was a great success. Participants was given PrEP along
with Truvada which is a pill that contains tenofovir and emtricitabine once per day.
The results of this study will reduced the spread of HIV (Nicol, et al, 2013).
Instances of the emergence and re-emergence of HIV/AIDS.
BIO 2070 MICRO WEEK 5 MIDTERM STUDY GUIDE
Brief description of HIV/AIDS
Living in the state that has one of the highest rate for individuals with AIDS
or HIV makes this disease a relevant topic that is near to me. I am so concerned
about our society especially the younger generations when it comes to the wide
rapid spread of AIDS throughout Georgia. According to the Center for Disease
Control CDC, every 1 in 51 persons in Georgia would be diagnosed with HIV
(CDC, 2016). HIV stands for human immunodeficiency virus. When left untreated,
HIV can lead to an acquired immunodeficiency syndrome (AIDS).
Work conducted by government departments to mitigate the impact of
HIV/AIDS.
The United States is working diligently with the Obama’s administration to
fight, cure, and prevent HIV. For the upcoming fiscal year President Obama has set
aside $788 million dollars for domestic HIV/AIDS prevention and research at the
CDC (CDC, 2016). There are many different studies being conducted to mitigate
, 2
the impact that HIV has on the US. I am going to choose one to discuss which is
PrEP. PrEP (pre-exposure prophylaxis) is used as an anti-HIV drug for individuals
who are not diagnosed with HIV. PrEP was released in 2014. When PrEP is taking
daily along with Truvada it reduces a person from being infected by 92 percent
(CDC, 2014).
Investigations, research studies, and other surveillance data analyses regarding
HIV/AIDS.
There is not a cure for HIV as of yet so, there are still 2.7 million people
infected with HIV in the world. Since, researchers cannot cure the infected patients
they decided to come up with a solution to curb the rapid spread of HIV. The first
phases of the PrEP study were administrated as a topical cream that was inserted
vaginally or rectally before and after sex but, not to be used no more than twice a
day. This study revealed promising results and allow researchers to experiment
more with PrEP. In 2007 phase two and three of this study was administered orally
to the participants and it was a great success. Participants was given PrEP along
with Truvada which is a pill that contains tenofovir and emtricitabine once per day.
The results of this study will reduced the spread of HIV (Nicol, et al, 2013).
Instances of the emergence and re-emergence of HIV/AIDS.
